Terms: = Colorectal cancer AND HER1, YOR227W AND Prognosis
6 results:
1. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract] [Full Text] [Related]
2. HER family receptor expression and prognosis in pancreatic cancer.
Bittoni A; Mandolesi A; Andrikou K; Santoni M; Alfonsi S; Lanese A; Loretelli C; Pellei C; Piva F; Scarpelli M; Cascinu S
Int J Biol Markers; 2015 Jul; 30(3):e327-32. PubMed ID: 26109364
[TBL] [Abstract] [Full Text] [Related]
3. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract] [Full Text] [Related]
4. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
[TBL] [Abstract] [Full Text] [Related]
5. From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer.
de Gramont A; de Gramont A; Chibaudel B; Bachet JB; Larsen AK; Tournigand C; Louvet C; André T;
Semin Oncol; 2011 Aug; 38(4):521-32. PubMed ID: 21810511
[TBL] [Abstract] [Full Text] [Related]
6. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer.
Press OA; Zhang W; Gordon MA; Yang D; Lurje G; Iqbal S; El-Khoueiry A; Lenz HJ
Cancer Res; 2008 Apr; 68(8):3037-42. PubMed ID: 18413774
[TBL] [Abstract] [Full Text] [Related]
